Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $210.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price increased by Needham & Company LLC from $205.00 to $210.00 in a research report released on Wednesday,Benzinga reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other research analysts also recently commented on the company. TD Cowen lowered their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, Piper Sandler reissued an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $182.47.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $143.53 on Wednesday. The company has a market cap of $8.68 billion, a P/E ratio of 20.22, a PEG ratio of 1.04 and a beta of 0.56. The stock has a fifty day moving average price of $126.28 and a 200 day moving average price of $118.79. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $148.06.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 5,053 shares of company stock valued at $617,442 over the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. CWA Asset Management Group LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at $9,335,000. Moloney Securities Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at $464,000. Finally, Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.